SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

The FDA's issuance of a Complete Response Letter (CRL) for Regenxbio's RGX-121 gene therapy for Hunter syndrome is driving intense conversation, with the community expressing significant concerns about the trial design, financial implications, and potential dilution amidst broader scrutiny of gene therapy development.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid anticipation for its upcoming earnings and significant market speculation regarding the uncertain fate of a House-passed bill to extend ACA subsidies; the community remains sharply divided, with some foreseeing a major re-rating due to policy tailwinds and execution, while others highlight financial challenges and broader sector headwinds.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is generating significant buzz following its Nasdaq listing, a recent financing round, and a reverse stock split, sparking an active community debate on the revolutionary potential of its SAT-3247 drug for Duchenne muscular dystrophy against concerns regarding dilution and the early stage of its clinical development.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals is trending due to a blowout quarterly earnings report that exceeded estimates, with the community actively discussing its perceived undervaluation and anticipating a significant price surge, bolstered by strong precious metals market conditions.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog (DDOG) is trending amidst high anticipation for its upcoming earnings report, with the community debating its strong position as an AI beneficiary and observability leader against concerns over competitive pressures and a broader software sector valuation reset.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimates for Pharming Group Increased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Pharming Group in a note issued to...

Pharming Group Q4 EPS Forecast Increased by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2025 earnings per share estimates for shares of Pharming Group in a note...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming...

<ul class="summary-bullets"><li>FDA feedback focused on dosing and testing questions, not safety or effectiveness concerns.</li><li>Joenja’s existing approval and sales in patients aged 12 and older remain unchanged.</li><li>Pharming said it plans to work with regulators and pursue a resubmission path.</li></ul>Pharming Group shares drew heightened retail chatter on Monday after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its application to expand the use of Joenja in younger pediatric patients, while signaling confidence it can address the agency’s concerns.<h2 class="st-heading-2">FDA Requests Additional Pediatric Data</h2>Dutch drug developer Pharming announced that it had received a Complete Response Letter from the FDA on its filing for the approval of Joenja in children aged 4-11 with activated phosphoinositide 3-kinase delta syndrome (APDS).APDS is a rare primary immunodeficiency disorder in which the immune system does not function properly, resulting in recurrent infections and other complications associated with immune dysfunction. Pharming’s Joenja is an oral medication indicated to treat APDS.The company said the FDA was concerned that younger children may not be receiving sufficient doses at the proposed levels and requested additional data to confirm appropriate dosing in younger patients. The agency also flagged a technical issue with a manufacturing test and requested additional information.Pharming expressed confidence that it can resolve both inquiries. The company added that it plans to meet with the FDA to discuss next steps for resubmission, including a Type A meeting.<h2 class="st-heading-2">Approval For Older Patients Unaffected</h2>The company emphasized that the Complete Response Letter does not impact Joenja’s existing FDA approval for adult and pediatric patients aged 12 years and older, which has been in place since March 2023.CEO Fabrice Chouraqui said Pharming remains focused on making Joenja available to younger children with APDS, noting that there are currently no approved targeted treatments globally for patients under the age of 12.<h2 class="st-heading-2">Trial Results Backing The Application</h2>The application was backed by data from a late-stage clinical study in children aged 4 to 11. Pharming said that over 12 weeks of treatment, children showed reduced lymph node swelling and healthier immune cell levels, signs that the drug was helping correct the immune problem caused by APDS.Safety data from up to eight months of treatment were also included in the submission. The company said all treatment-emergent adverse events were mild to moderate, no drug-related serious adverse events were reported, and all patients completed the 12-week treatment period.In October 2025, the FDA granted the application Priority Review, citing the potential for significant improvements in the treatment of a serious condition.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Pharming was ‘bullish’ amid ‘high’ message volume ahead of the company’s Virtual Investor Day on Tuesday.One user called the FDA response a “soft” CRL, noting that it focused on dosing and testing issues rather than safety, and that Joenja remains approved and generating revenue for patients aged 12 and older.<stembedurl>https://stocktwits.com/BioSpecialOne/message/643641905</stembedurl>Another user said, “will buy the dip. Hopefully it’s a large drop”<stembedurl>https://stocktwits.com/CrispDry/message/643612689</stembedurl><a href="https://stocktwits.com/symbol/PHAR">U.S.-listed shares of Pharming</a> have surged over 130% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Pharming logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking

The company expressed confidence that it can resolve the FDA’s inquiries. 

Equity

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest...

Pharming Group (OTCMKTS:PHGUF) Sets New 1-Year High - Here's What Happened

Pharming Group (OTCMKTS:PHGUF) Hits New 12-Month High - Time to Buy...

Pharming Group (NASDAQ:PHAR) Lowered to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research note on Thursday...

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell...

Pharming Group (NASDAQ:PHAR) Shares Up 4.4% - Should You Buy?

Pharming Group (NASDAQ:PHAR) Trading 4.4% Higher - Here's What Happened...

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Should You Buy?

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Pharming Group N.V. - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$16.37
Prev Close	$16.09
Open	$16.28
Dividend Yield	0.00%
50-Day Moving Average	$17.71
Beta	0.47
Avg. Volume	30,004.95
PE Ratio	1,117.36

52-Week High	$21.34
52-Week Low	$7.50
Market Capitalization	$1.13B
EPS (Annual)	-$0.1761
Price to Book	4.17
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PHAR
Pharming Group

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHAR News

PHARPharming Group